LM22A-4
LM22A-4 is a synthetic, selective small-molecule partial agonist of TrkB (EC 50 for TrkB activation = 200–500 pM; IC 50 for inhibition of BDNF binding to TrkB = 47 nM; IA = ~85%), the main receptor of brain-derived neurotrophic factor.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
LM22A-4 is a synthetic, selective small-molecule partial agonist of TrkB (EC 50 for TrkB activation = 200–500 pM; IC 50 for inhibition of BDNF binding to TrkB = 47 nM; IA = ~85%), the main receptor of brain-derived neurotrophic factor. It has been found to possess poor blood-brain-barrier penetration when administered systemically, so LM22A-4 has been given to animals instead via intranasal administration, with central nervous system TrkB activation observed.
The compound produces neurogenic and neuroprotective effects in animals, and shows beneficial effects on respiration in animal models of Rett syndrome.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329034861 under CC BY-SA 4.0; modifications have been made.